Armistice Capital LLC grew its position in shares of FibroGen, Inc. (NASDAQ:FGEN - Free Report) by 23.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,764,000 shares of the biopharmaceutical company's stock after acquiring an additional 1,872,000 shares during the quarter. Armistice Capital LLC owned 9.93% of FibroGen worth $8,654,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the company. Fox Run Management L.L.C. bought a new stake in shares of FibroGen during the 3rd quarter worth approximately $37,000. SG Americas Securities LLC raised its stake in shares of FibroGen by 79.8% during the 4th quarter. SG Americas Securities LLC now owns 112,783 shares of the biopharmaceutical company's stock worth $100,000 after purchasing an additional 50,073 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of FibroGen during the 3rd quarter worth approximately $45,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of FibroGen during the 3rd quarter worth approximately $94,000. Finally, Algert Global LLC raised its stake in shares of FibroGen by 488.4% during the 3rd quarter. Algert Global LLC now owns 161,550 shares of the biopharmaceutical company's stock worth $139,000 after purchasing an additional 134,094 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company's stock.
FibroGen Stock Performance
FGEN traded down $0.02 during trading hours on Thursday, reaching $1.19. The company's stock had a trading volume of 1,939,489 shares, compared to its average volume of 2,656,973. FibroGen, Inc. has a 52 week low of $0.33 and a 52 week high of $18.62. The company's 50-day moving average is $1.30 and its 200-day moving average is $1.34. The firm has a market cap of $118.37 million, a PE ratio of -0.49 and a beta of 0.82.
FibroGen (NASDAQ:FGEN - Get Free Report) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.02). The company had revenue of $55.90 million during the quarter, compared to analyst estimates of $41.00 million. Equities analysts anticipate that FibroGen, Inc. will post -1.05 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, William Blair reiterated a "market perform" rating on shares of FibroGen in a research note on Monday. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating to the company's stock. Based on data from MarketBeat.com, FibroGen currently has a consensus rating of "Hold" and an average price target of $2.00.
View Our Latest Analysis on FibroGen
FibroGen Company Profile
(Free Report)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Featured Articles
- Five stocks we like better than FibroGen
- Where to Find Earnings Call Transcripts
- Novavax Stock’s Recent Surge and Future Potential
- How to Calculate Inflation Rate
- Investing in Biotech: High Risk for a Potentially High Reward
- Most active stocks: Dollar volume vs share volume
- GameStop Stock Update: What’s Driving Today’s Prices?
→ Biden Nomination CANCELED? (From The Freeport Society) (Ad)
Should you invest $1,000 in FibroGen right now?
Before you consider FibroGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FibroGen wasn't on the list.
While FibroGen currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
20 High-Yield Dividend Stocks that Could Ruin Your Retirement
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
